Great consistent results but it's curious that we didn't get data for the patients in stage 2 for the nsclc or the head and neck portions. The nsclc stage 2 has been fully recruited for a while so some patients would of been reportable.
personally dont think it's a bad thing, if anything Merck might be wanting these results to stay to themselves and IMM as leverage is lost if the results are released and as good as we've got so far.
Ann: Improving results from stage 1 of TACTI-002 ph II trial, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.599M | 5.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 65758 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 6777 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |